2017-2022 Global and Japan Benign Prostatic Hyperplasia Medication Market Analysis Report

August 2017 | 124 pages | ID: 21D15B7538DEN
JP Research

Abstracts

The global Benign Prostatic Hyperplasia Medication market is valued at XX million USD in 2016 and is expected to reach XX million USD by the end of 2017, growing at a CAGR of XX% between 2016 and 2022.

Japan plays an important role in global market, with market size of xx million USD in 2016 and will be xx million USD in 2017, with a CAGR of xx%.

This report, with focus on top players in the global and Japan, studies the Benign Prostatic Hyperplasia Medication market's development status and future trend in the global and Japan. It splits Benign Prostatic Hyperplasia Medication market by type and by applications to fully and deeply research and reveal market profile and prospect.

The major players include

• MSD PHARMA (SINGAPORE) PTE.LTD.
• Merck Sharp & Dohme Limited
• GlaxoSmithKline (Ireland) Limited
• Pfizer Pharma GmbH
• Sanofi-Aventis France
• ABBOTT LABORATORIES
• Astellas Pharma Inc.
• AMNEAL PHARMS
• ANCHEN PHARMS
• APOTEX INC
• ASCENT PHARMS INC
• AUROBINDO PHARMA
• BARR
• BIONPHARMA INC
• BOEHRINGER INGELHEIM
• BRECKENRIDGE PHARM
• CIPLA LTD
• AUROBINDO PHARMA LIMITED IN 500 038 Hyderabad
• Bioindustria L.I.M. S.p.A. IT 15067 Novi Ligure
• CADILA HEALTHCARE LIMITED IN 391 440 Dabhasa Village
• CIPLA LIMITED IN 400 013 Mumbai
• CRYSTAL PHARMA S.A.U. ES 47151 Boecillo
• DR. REDDY'S LABORATORIES LIMITED IN 500 034 Hyderabad
• EXCELLA GMBH & CO. KG DE 90537 Feucht
• Farmak A.S. CZ 779 00 Olomouc
• HETERO LABS LIMITED IN 500 018 Hyderabad
• Hubei Gedian Humanwell Pharmaceutical Co., Ltd. CN 436 070 E-Zhou
• MSN LABORATORIES PRIVATE LIMITED IN 502 329 Rudraram Village

Geographically, this report splits the Global market into the following regions:

• Asia Pacific
• Japan
• Tokyo
• Yokohama
• Osaka
• Nagoya
• Others
• China
• Korea
• India
• Others
• Europe
• France
• Germany
• United Kingdom
• Italy
• Russia
• Others
• North America
• United States
• Canada
• Latin America
• Brazil
• Mexico
• Others
• Southeast Asia
• Singapore
• Malaysia
• Vietnam
• Myanmar
• Thailand
• Indonesia
• Philippines
• Others
• Middle East & Africa
• Saudi Arabia
• Iran
• UAE
• Turkey
• Israel
• Egypt
• South Africa
• Others

On the basis of product, the Benign Prostatic Hyperplasia Medication market is primarily split into

by 5α-reductase inhibitors

• Finasteride
• Dutasteride
• Epristeride

by α-receptor antagonist

• Pheoxbenzamine
• Doxazosin
• Alfuzosin
• Terazosin
• Prarizonaosin
• Tamsulosin
• Naftopidil

by Plant Preparations

• Prostat
• Cernilton
• Compound blue palm fruit

byOthers

• Flavoxate
• glu-ala-glycine

Key Applications

• urinary surgery
• Pharmacy
• Hospital
• Clinic

Contents

1 BENIGN PROSTATIC HYPERPLASIA MEDICATION OVERVIEW

1.1 Product Overview and Scope of Benign Prostatic Hyperplasia Medication
1.2 Global and Japan Benign Prostatic Hyperplasia Medication Market by Applications/End Users
  1.2.1 Japan Benign Prostatic Hyperplasia Medication Sales () and Market Share Comparison by Applications (2012-2017)
    1.2.1.1 Japan Benign Prostatic Hyperplasia Medication Sales () and Market Share by Applications (2012-2017)
    1.2.1.2 Japan Benign Prostatic Hyperplasia Medication Sales Growth Rate (%) by Applications (2012-2017)
    1.2.1.3 Market Drivers and Opportunities
  1.2.2 Japan Benign Prostatic Hyperplasia Medication Sales () and Market Share Comparison by Applications (2012-2017)
  1.2.3 Global Benign Prostatic Hyperplasia Medication Sales by Application (2012-2017)
    1.2.3.1 Global Benign Prostatic Hyperplasia Medication Sales () and Market Share by Applications (2012-2017)
    1.2.3.2 Global Benign Prostatic Hyperplasia Medication Sales Growth Rate (%) by Applications (2012-2017)
    1.2.3.3 Market Drivers and Opportunities
  1.2.4 Global Benign Prostatic Hyperplasia Medication Sales () and Market Share Comparison by Applications (2012-2017)
  1.2.5 urinary surgery
  1.2.6 Pharmacy
  1.2.7 Hospital
  1.2.8 Clinic
1.3 Global and Japan Market Size (Sales and Revenue) of Benign Prostatic Hyperplasia Medication (2012-2017)
  1.3.1 Japan Market Size (Sales and Revenue) of Benign Prostatic Hyperplasia Medication (2012-2017)
    1.3.1.1 Japan Benign Prostatic Hyperplasia Medication Sales () and Growth Rate (%) (2012-2017)
    1.3.1.2 Japan Benign Prostatic Hyperplasia Medication Revenue (Million USD) and Growth Rate (2012-2017)
  1.3.2 Global Market Size (Sales and Revenue) of Benign Prostatic Hyperplasia Medication (2012-2017)
    1.3.2.1 Global Benign Prostatic Hyperplasia Medication Sales () and Growth Rate (%) (2012-2017)
    1.3.2.2 Global Benign Prostatic Hyperplasia Medication Revenue (Million USD) and Growth Rate (2012-2017)
1.4 Global and Japan Classification of Benign Prostatic Hyperplasia Medication by 5α-reductase inhibitors
  1.4.1 Japan Benign Prostatic Hyperplasia Medication Sales () and Market Share by 5α-reductase inhibitors (2012-2017)
  1.4.2 Global Benign Prostatic Hyperplasia Medication Sales () and Market Share by 5α-reductase inhibitors (2012-2017)
  1.4.3 Japan Benign Prostatic Hyperplasia Medication Revenue (Million USD) and Market Share by 5α-reductase inhibitors (2012-2017)
  1.4.4 Global Benign Prostatic Hyperplasia Medication Revenue (Million USD) and Market Share by 5α-reductase inhibitors (2012-2017)
  1.4.5 Japan Benign Prostatic Hyperplasia Medication Price () by 5α-reductase inhibitors (2012-2017)
  1.4.6 Global Benign Prostatic Hyperplasia Medication Price () by 5α-reductase inhibitors (2012-2017)
  1.4.7 Japan Benign Prostatic Hyperplasia Medication Sales Growth Rate (%) by 5α-reductase inhibitors (2012-2017)
  1.4.8 Global Benign Prostatic Hyperplasia Medication Sales Growth Rate (%) by 5α-reductase inhibitors (2012-2017)
  1.4.9 Finasteride
  1.4.10 Dutasteride
  1.4.11 Epristeride
1.5 Global and Japan Classification of Benign Prostatic Hyperplasia Medication by α-receptor antagonist
  1.5.1 Japan Benign Prostatic Hyperplasia Medication Sales () and Market Share by α-receptor antagonist (2012-2017)
  1.5.2 Global Benign Prostatic Hyperplasia Medication Sales () and Market Share by α-receptor antagonist (2012-2017)
  1.5.3 Japan Benign Prostatic Hyperplasia Medication Revenue (Million USD) and Market Share by α-receptor antagonist (2012-2017)
  1.5.4 Global Benign Prostatic Hyperplasia Medication Revenue (Million USD) and Market Share by α-receptor antagonist (2012-2017)
  1.5.5 Japan Benign Prostatic Hyperplasia Medication Price () by α-receptor antagonist (2012-2017)
  1.5.6 Global Benign Prostatic Hyperplasia Medication Price () by α-receptor antagonist (2012-2017)
  1.5.7 Japan Benign Prostatic Hyperplasia Medication Sales Growth Rate (%) by α-receptor antagonist (2012-2017)
  1.5.8 Global Benign Prostatic Hyperplasia Medication Sales Growth Rate (%) by α-receptor antagonist (2012-2017)
  1.5.9 Pheoxbenzamine
  1.5.10 Doxazosin
  1.5.11 Alfuzosin
  1.5.12 Terazosin
  1.5.13 Prarizonaosin
  1.5.14 Tamsulosin
  1.5.15 Naftopidil
1.6 Global and Japan Classification of Benign Prostatic Hyperplasia Medication by Plant Preparations
  1.6.1 Japan Benign Prostatic Hyperplasia Medication Sales () and Market Share by Plant Preparations (2012-2017)
  1.6.2 Global Benign Prostatic Hyperplasia Medication Sales () and Market Share by Plant Preparations (2012-2017)
  1.6.3 Japan Benign Prostatic Hyperplasia Medication Revenue (Million USD) and Market Share by Plant Preparations (2012-2017)
  1.6.4 Global Benign Prostatic Hyperplasia Medication Revenue (Million USD) and Market Share by Plant Preparations (2012-2017)
  1.6.5 Japan Benign Prostatic Hyperplasia Medication Price () by Plant Preparations (2012-2017)
  1.6.6 Global Benign Prostatic Hyperplasia Medication Price () by Plant Preparations (2012-2017)
  1.6.7 Japan Benign Prostatic Hyperplasia Medication Sales Growth Rate (%) by Plant Preparations (2012-2017)
  1.6.8 Global Benign Prostatic Hyperplasia Medication Sales Growth Rate (%) by Plant Preparations (2012-2017)
  1.6.9 Prostat
  1.6.10 Cernilton
  1.6.11 Compound blue palm fruit
1.7 Global and Japan Classification of Benign Prostatic Hyperplasia Medication by Others
  1.7.1 Japan Benign Prostatic Hyperplasia Medication Sales () and Market Share by Others (2012-2017)
  1.7.2 Global Benign Prostatic Hyperplasia Medication Sales () and Market Share by Others (2012-2017)
  1.7.3 Japan Benign Prostatic Hyperplasia Medication Revenue (Million USD) and Market Share by Others (2012-2017)
  1.7.4 Global Benign Prostatic Hyperplasia Medication Revenue (Million USD) and Market Share by Others (2012-2017)
  1.7.5 Japan Benign Prostatic Hyperplasia Medication Price () by Others (2012-2017)
  1.7.6 Global Benign Prostatic Hyperplasia Medication Price () by Others (2012-2017)
  1.7.7 Japan Benign Prostatic Hyperplasia Medication Sales Growth Rate (%) by Others (2012-2017)
  1.7.8 Global Benign Prostatic Hyperplasia Medication Sales Growth Rate (%) by Others (2012-2017)
  1.7.9 Flavoxate
  1.7.10 glu-ala-glycine

2 GLOBAL AND JAPAN BENIGN PROSTATIC HYPERPLASIA MEDICATION MARKET COMPETITION BY PLAYERS/MANUFACTURERS

2.1 Japan Benign Prostatic Hyperplasia Medication Market Competition by Players/Manufacturers
  2.1.1 Japan Benign Prostatic Hyperplasia Medication Sales and Market Share of Key Players/Manufacturers (2012-2017)
  2.1.2 Japan Benign Prostatic Hyperplasia Medication Revenue and Share by Players/Manufacturers (2012-2017)
  2.1.3 Japan Benign Prostatic Hyperplasia Medication Average Price () by Players/Manufacturers (2012-2017)
  2.1.4 Japan Benign Prostatic Hyperplasia Medication Market Competitive Situation and Trends
    2.1.4.1 Japan Benign Prostatic Hyperplasia Medication Market Concentration Rate
    2.1.4.2 Japan Benign Prostatic Hyperplasia Medication Market Share of Top 3 and Top 5 Players/Manufacturers
    2.1.4.3 Mergers & Acquisitions, Expansion in Japan Market
  2.1.5 Japan Players/Manufacturers Benign Prostatic Hyperplasia Medication Manufacturing Base Distribution, Sales Area, Product Types
2.2 Global Benign Prostatic Hyperplasia Medication Market Competition by Players/Manufacturers
  2.2.1 Global Benign Prostatic Hyperplasia Medication Sales and Market Share of Key Players/Manufacturers (2012-2017)
  2.2.2 Global Benign Prostatic Hyperplasia Medication Revenue and Share by Players/Manufacturers (2012-2017)
  2.2.3 Global Benign Prostatic Hyperplasia Medication Average Price () by Players/Manufacturers (2012-2017)
  2.2.4 Global Benign Prostatic Hyperplasia Medication Market Competitive Situation and Trends
    2.2.4.1 Global Benign Prostatic Hyperplasia Medication Market Concentration Rate
    2.2.4.2 Global Benign Prostatic Hyperplasia Medication Market Share of Top 3 and Top 5 Players/Manufacturers
    2.2.4.3 Mergers & Acquisitions, Expansion in Global Market
  2.2.5 Global Players/Manufacturers Benign Prostatic Hyperplasia Medication Manufacturing Base Distribution, Sales Area, Product Types

3 GLOBAL AND JAPAN BENIGN PROSTATIC HYPERPLASIA MEDICATION SALES AND REVENUE BY REGIONS (2012-2017)

3.1 Asia Pacific Benign Prostatic Hyperplasia Medication Sales and Revenue by Regions (2012-2017)
  3.1.1 Japan Benign Prostatic Hyperplasia Medication Sales and Revenue (2012-2017)
    3.1.1.1 Japan Benign Prostatic Hyperplasia Medication Sales () and Market Share (2012-2017)
    3.1.1.2 Japan Benign Prostatic Hyperplasia Medication Revenue (Million USD) and Market Share (2012-2017)
    3.1.1.3 Japan Benign Prostatic Hyperplasia Medication Price ()(2012-2017)
  3.1.2 China Benign Prostatic Hyperplasia Medication Sales and Revenue (2012-2017)
    3.1.2.1 China Benign Prostatic Hyperplasia Medication Sales () and Market Share (2012-2017)
    3.1.2.2 China Benign Prostatic Hyperplasia Medication Revenue (Million USD) and Market Share (2012-2017)
    3.1.2.3 China Benign Prostatic Hyperplasia Medication Price ()(2012-2017)
  3.1.3 Korea Benign Prostatic Hyperplasia Medication Sales and Revenue (2012-2017)
    3.1.3.1 Korea Benign Prostatic Hyperplasia Medication Sales () and Market Share (2012-2017)
    3.1.3.2 Korea Benign Prostatic Hyperplasia Medication Revenue (Million USD) and Market Share (2012-2017)
    3.1.3.3 Korea Benign Prostatic Hyperplasia Medication Price ()(2012-2017)
  3.1.4 India Benign Prostatic Hyperplasia Medication Sales and Revenue (2012-2017)
    3.1.4.1 India Benign Prostatic Hyperplasia Medication Sales () and Market Share (2012-2017)
    3.1.4.2 India Benign Prostatic Hyperplasia Medication Revenue (Million USD) and Market Share (2012-2017)
    3.1.4.3 India Benign Prostatic Hyperplasia Medication Price ()(2012-2017)
  3.1.5 Others Benign Prostatic Hyperplasia Medication Sales and Revenue (2012-2017)
    3.1.5.1 Others Benign Prostatic Hyperplasia Medication Sales () and Market Share (2012-2017)
    3.1.5.2 Others Benign Prostatic Hyperplasia Medication Revenue (Million USD) and Market Share (2012-2017)
    3.1.5.3 Others Benign Prostatic Hyperplasia Medication Price ()(2012-2017)
3.2 Europe Benign Prostatic Hyperplasia Medication Sales and Revenue by Regions (2012-2017)
  3.2.1 France Benign Prostatic Hyperplasia Medication Sales and Revenue (2012-2017)
    3.2.1.1 France Benign Prostatic Hyperplasia Medication Sales () and Market Share (2012-2017)
    3.2.1.2 France Benign Prostatic Hyperplasia Medication Revenue (Million USD) and Market Share (2012-2017)
    3.2.1.3 France Benign Prostatic Hyperplasia Medication Price ()(2012-2017)
  3.2.2 Germany Benign Prostatic Hyperplasia Medication Sales and Revenue (2012-2017)
    3.2.2.1 Germany Benign Prostatic Hyperplasia Medication Sales () and Market Share (2012-2017)
    3.2.2.2 Germany Benign Prostatic Hyperplasia Medication Revenue (Million USD) and Market Share (2012-2017)
    3.2.2.3 Germany Benign Prostatic Hyperplasia Medication Price ()(2012-2017)
  3.2.3 United Kingdom Benign Prostatic Hyperplasia Medication Sales and Revenue (2012-2017)
    3.2.3.1 United Kingdom Benign Prostatic Hyperplasia Medication Sales () and Market Share (2012-2017)
    3.2.3.2 United Kingdom Benign Prostatic Hyperplasia Medication Revenue (Million USD) and Market Share (2012-2017)
    3.2.3.3 United Kingdom Benign Prostatic Hyperplasia Medication Price ()(2012-2017)
  3.2.4 Italy Benign Prostatic Hyperplasia Medication Sales and Revenue (2012-2017)
    3.2.4.1 Italy Benign Prostatic Hyperplasia Medication Sales () and Market Share (2012-2017)
    3.2.4.2 Italy Benign Prostatic Hyperplasia Medication Revenue (Million USD) and Market Share (2012-2017)
    3.2.4.3 Italy Benign Prostatic Hyperplasia Medication Price ()(2012-2017)
  3.2.5 Russia Benign Prostatic Hyperplasia Medication Sales and Revenue (2012-2017)
    3.2.5.1 Russia Benign Prostatic Hyperplasia Medication Sales () and Market Share (2012-2017)
    3.2.5.2 Russia Benign Prostatic Hyperplasia Medication Revenue (Million USD) and Market Share (2012-2017)
    3.2.5.3 Russia Benign Prostatic Hyperplasia Medication Price ()(2012-2017)
  3.2.6 Others Benign Prostatic Hyperplasia Medication Sales and Revenue (2012-2017)
    3.2.6.1 Others Benign Prostatic Hyperplasia Medication Sales () and Market Share (2012-2017)
    3.2.6.2 Others Benign Prostatic Hyperplasia Medication Revenue (Million USD) and Market Share (2012-2017)
    3.2.6.3 Others Benign Prostatic Hyperplasia Medication Price ()(2012-2017)
3.3 North America Benign Prostatic Hyperplasia Medication Sales and Revenue by Regions (2012-2017)
  3.3.1 United States Benign Prostatic Hyperplasia Medication Sales and Revenue (2012-2017)
    3.3.1.1 United States Benign Prostatic Hyperplasia Medication Sales () and Market Share (2012-2017)
    3.3.1.2 United States Benign Prostatic Hyperplasia Medication Revenue (Million USD) and Market Share (2012-2017)
    3.3.1.3 United States Benign Prostatic Hyperplasia Medication Price ()(2012-2017)
  3.3.2 Canada Benign Prostatic Hyperplasia Medication Sales and Revenue (2012-2017)
    3.3.2.1 Canada Benign Prostatic Hyperplasia Medication Sales () and Market Share (2012-2017)
    3.3.2.2 Canada Benign Prostatic Hyperplasia Medication Revenue (Million USD) and Market Share (2012-2017)
    3.3.2.3 Canada Benign Prostatic Hyperplasia Medication Price ()(2012-2017)
3.4 Latin America Benign Prostatic Hyperplasia Medication Sales and Revenue by Regions (2012-2017)
  3.4.1 Brazil Benign Prostatic Hyperplasia Medication Sales and Revenue (2012-2017)
    3.4.1.1 Brazil Benign Prostatic Hyperplasia Medication Sales () and Market Share (2012-2017)
    3.4.1.2 Brazil Benign Prostatic Hyperplasia Medication Revenue (Million USD) and Market Share (2012-2017)
    3.4.1.3 Brazil Benign Prostatic Hyperplasia Medication Price ()(2012-2017)
  3.4.2 Mexico Benign Prostatic Hyperplasia Medication Sales and Revenue (2012-2017)
    3.4.2.1 Mexico Benign Prostatic Hyperplasia Medication Sales () and Market Share (2012-2017)
    3.4.2.2 Mexico Benign Prostatic Hyperplasia Medication Revenue (Million USD) and Market Share (2012-2017)
    3.4.2.3 Mexico Benign Prostatic Hyperplasia Medication Price ()(2012-2017)
  3.4.3 Others Benign Prostatic Hyperplasia Medication Sales and Revenue (2012-2017)
    3.4.3.1 Others Benign Prostatic Hyperplasia Medication Sales () and Market Share (2012-2017)
    3.4.3.2 Others Benign Prostatic Hyperplasia Medication Revenue (Million USD) and Market Share (2012-2017)
    3.4.3.3 Others Benign Prostatic Hyperplasia Medication Price ()(2012-2017)
3.5 Southeast Asia Benign Prostatic Hyperplasia Medication Sales and Revenue by Regions (2012-2017)
  3.5.1 Singapore Benign Prostatic Hyperplasia Medication Sales and Revenue (2012-2017)
    3.5.1.1 Singapore Benign Prostatic Hyperplasia Medication Sales () and Market Share (2012-2017)
    3.5.1.2 Singapore Benign Prostatic Hyperplasia Medication Revenue (Million USD) and Market Share (2012-2017)
    3.5.1.3 Singapore Benign Prostatic Hyperplasia Medication Price ()(2012-2017)
  3.5.2 Malaysia Benign Prostatic Hyperplasia Medication Sales and Revenue (2012-2017)
    3.5.2.1 Malaysia Benign Prostatic Hyperplasia Medication Sales () and Market Share (2012-2017)
    3.5.2.2 Malaysia Benign Prostatic Hyperplasia Medication Revenue (Million USD) and Market Share (2012-2017)
    3.5.2.3 Malaysia Benign Prostatic Hyperplasia Medication Price ()(2012-2017)
  3.5.3 Vietnam Benign Prostatic Hyperplasia Medication Sales and Revenue (2012-2017)
    3.5.3.1 Vietnam Benign Prostatic Hyperplasia Medication Sales () and Market Share (2012-2017)
    3.5.3.2 Vietnam Benign Prostatic Hyperplasia Medication Revenue (Million USD) and Market Share (2012-2017)
    3.5.3.3 Vietnam Benign Prostatic Hyperplasia Medication Price ()(2012-2017)
  3.5.4 Myanmar Benign Prostatic Hyperplasia Medication Sales and Revenue (2012-2017)
    3.5.4.1 Myanmar Benign Prostatic Hyperplasia Medication Sales () and Market Share (2012-2017)
    3.5.4.2 Myanmar Benign Prostatic Hyperplasia Medication Revenue (Million USD) and Market Share (2012-2017)
    3.5.4.3 Myanmar Benign Prostatic Hyperplasia Medication Price ()(2012-2017)
  3.5.5 Thailand Benign Prostatic Hyperplasia Medication Sales and Revenue (2012-2017)
    3.5.5.1 Thailand Benign Prostatic Hyperplasia Medication Sales () and Market Share (2012-2017)
    3.5.5.2 Thailand Benign Prostatic Hyperplasia Medication Revenue (Million USD) and Market Share (2012-2017)
    3.5.5.3 Thailand Benign Prostatic Hyperplasia Medication Price ()(2012-2017)
  3.5.6 Indonesia Benign Prostatic Hyperplasia Medication Sales and Revenue (2012-2017)
    3.5.6.1 Indonesia Benign Prostatic Hyperplasia Medication Sales () and Market Share (2012-2017)
    3.5.6.2 Indonesia Benign Prostatic Hyperplasia Medication Revenue (Million USD) and Market Share (2012-2017)
    3.5.6.3 Indonesia Benign Prostatic Hyperplasia Medication Price ()(2012-2017)
  3.5.7 Philippines Benign Prostatic Hyperplasia Medication Sales and Revenue (2012-2017)
    3.5.7.1 Philippines Benign Prostatic Hyperplasia Medication Sales () and Market Share (2012-2017)
    3.5.7.2 Philippines Benign Prostatic Hyperplasia Medication Revenue (Million USD) and Market Share (2012-2017)
    3.5.7.3 Philippines Benign Prostatic Hyperplasia Medication Price ()(2012-2017)
  3.5.8 Others Benign Prostatic Hyperplasia Medication Sales and Revenue (2012-2017)
    3.5.8.1 Others Benign Prostatic Hyperplasia Medication Sales () and Market Share (2012-2017)
    3.5.8.2 Others Benign Prostatic Hyperplasia Medication Revenue (Million USD) and Market Share (2012-2017)
    3.5.8.3 Others Benign Prostatic Hyperplasia Medication Price ()(2012-2017)
3.6 Middle East & Africa Benign Prostatic Hyperplasia Medication Sales and Revenue by Regions (2012-2017)
  3.6.1 Saudi Arabia Benign Prostatic Hyperplasia Medication Sales and Revenue (2012-2017)
    3.6.1.1 Saudi Arabia Benign Prostatic Hyperplasia Medication Sales () and Market Share (2012-2017)
    3.6.1.2 Saudi Arabia Benign Prostatic Hyperplasia Medication Revenue (Million USD) and Market Share (2012-2017)
    3.6.1.3 Saudi Arabia Benign Prostatic Hyperplasia Medication Price ()(2012-2017)
  3.6.2 Iran Benign Prostatic Hyperplasia Medication Sales and Revenue (2012-2017)
    3.6.2.1 Iran Benign Prostatic Hyperplasia Medication Sales () and Market Share (2012-2017)
    3.6.2.2 Iran Benign Prostatic Hyperplasia Medication Revenue (Million USD) and Market Share (2012-2017)
    3.6.2.3 Iran Benign Prostatic Hyperplasia Medication Price ()(2012-2017)
  3.6.3 UAE Benign Prostatic Hyperplasia Medication Sales and Revenue (2012-2017)
    3.6.3.1 UAE Benign Prostatic Hyperplasia Medication Sales () and Market Share (2012-2017)
    3.6.3.2 UAE Benign Prostatic Hyperplasia Medication Revenue (Million USD) and Market Share (2012-2017)
    3.6.3.3 UAE Benign Prostatic Hyperplasia Medication Price ()(2012-2017)
  3.6.4 Turkey Benign Prostatic Hyperplasia Medication Sales and Revenue (2012-2017)
    3.6.4.1 Turkey Benign Prostatic Hyperplasia Medication Sales () and Market Share (2012-2017)
    3.6.4.2 Turkey Benign Prostatic Hyperplasia Medication Revenue (Million USD) and Market Share (2012-2017)
    3.6.4.3 Turkey Benign Prostatic Hyperplasia Medication Price ()(2012-2017)
  3.6.5 Israel Benign Prostatic Hyperplasia Medication Sales and Revenue (2012-2017)
    3.6.5.1 Israel Benign Prostatic Hyperplasia Medication Sales () and Market Share (2012-2017)
    3.6.5.2 Israel Benign Prostatic Hyperplasia Medication Revenue (Million USD) and Market Share (2012-2017)
    3.6.5.3 Israel Benign Prostatic Hyperplasia Medication Price ()(2012-2017)
  3.6.6 Egypt Benign Prostatic Hyperplasia Medication Sales and Revenue (2012-2017)
    3.6.6.1 Egypt Benign Prostatic Hyperplasia Medication Sales () and Market Share (2012-2017)
    3.6.6.2 Egypt Benign Prostatic Hyperplasia Medication Revenue (Million USD) and Market Share (2012-2017)
    3.6.6.3 Egypt Benign Prostatic Hyperplasia Medication Price ()(2012-2017)
  3.6.7 South Africa Benign Prostatic Hyperplasia Medication Sales and Revenue (2012-2017)
    3.6.7.1 South Africa Benign Prostatic Hyperplasia Medication Sales () and Market Share (2012-2017)
    3.6.7.2 South Africa Benign Prostatic Hyperplasia Medication Revenue (Million USD) and Market Share (2012-2017)
    3.6.7.3 South Africa Benign Prostatic Hyperplasia Medication Price ()(2012-2017)
  3.6.8 Others Benign Prostatic Hyperplasia Medication Sales and Revenue (2012-2017)
    3.6.8.1 Others Benign Prostatic Hyperplasia Medication Sales () and Market Share (2012-2017)
    3.6.8.2 Others Benign Prostatic Hyperplasia Medication Revenue (Million USD) and Market Share (2012-2017)
    3.6.8.3 Others Benign Prostatic Hyperplasia Medication Price ()(2012-2017)

4 GLOBAL AND JAPAN BENIGN PROSTATIC HYPERPLASIA MEDICATION PLAYERS/MANUFACTURERS PROFILES AND SALES DATA

4.1 MSD PHARMA (SINGAPORE) PTE.LTD.
  4.1.1 Company Basic Information, Manufacturing Base and Competitors
  4.1.2 Benign Prostatic Hyperplasia Medication Product Category, Application and Specification
    4.1.2.1 Product A
    4.1.2.2 Product B
  4.1.3 MSD PHARMA (SINGAPORE) PTE.LTD. Benign Prostatic Hyperplasia Medication Sales (), Revenue (Million USD), Price () and Gross Margin (%)(2012-2017)
  4.1.4 Main Business/Business Overview
4.2 Merck Sharp & Dohme Limited
  4.2.1 Company Basic Information, Manufacturing Base and Competitors
  4.2.2 Benign Prostatic Hyperplasia Medication Product Category, Application and Specification
    4.2.2.1 Product A
    4.2.2.2 Product B
  4.2.3 Merck Sharp & Dohme Limited Benign Prostatic Hyperplasia Medication Sales (), Revenue (Million USD), Price () and Gross Margin (%)(2012-2017)
  4.2.4 Main Business/Business Overview
4.3 GlaxoSmithKline (Ireland) Limited
  4.3.1 Company Basic Information, Manufacturing Base and Competitors
  4.3.2 Benign Prostatic Hyperplasia Medication Product Category, Application and Specification
    4.3.2.1 Product A
    4.3.2.2 Product B
  4.3.3 GlaxoSmithKline (Ireland) Limited Benign Prostatic Hyperplasia Medication Sales (), Revenue (Million USD), Price () and Gross Margin (%)(2012-2017)
  4.3.4 Main Business/Business Overview
4.4 Pfizer Pharma GmbH
  4.4.1 Company Basic Information, Manufacturing Base and Competitors
  4.4.2 Benign Prostatic Hyperplasia Medication Product Category, Application and Specification
    4.4.2.1 Product A
    4.4.2.2 Product B
  4.4.3 Pfizer Pharma GmbH Benign Prostatic Hyperplasia Medication Sales (), Revenue (Million USD), Price () and Gross Margin (%)(2012-2017)
  4.4.4 Main Business/Business Overview
4.5 Sanofi-Aventis France
  4.5.1 Company Basic Information, Manufacturing Base and Competitors
  4.5.2 Benign Prostatic Hyperplasia Medication Product Category, Application and Specification
    4.5.2.1 Product A
    4.5.2.2 Product B
  4.5.3 Sanofi-Aventis France Benign Prostatic Hyperplasia Medication Sales (), Revenue (Million USD), Price () and Gross Margin (%)(2012-2017)
  4.5.4 Main Business/Business Overview
4.6 ABBOTT LABORATORIES
  4.6.1 Company Basic Information, Manufacturing Base and Competitors
  4.6.2 Benign Prostatic Hyperplasia Medication Product Category, Application and Specification
    4.6.2.1 Product A
    4.6.2.2 Product B
  4.6.3 ABBOTT LABORATORIES Benign Prostatic Hyperplasia Medication Sales (), Revenue (Million USD), Price () and Gross Margin (%)(2012-2017)
  4.6.4 Main Business/Business Overview
4.7 Astellas Pharma Inc.
  4.7.1 Company Basic Information, Manufacturing Base and Competitors
  4.7.2 Benign Prostatic Hyperplasia Medication Product Category, Application and Specification
    4.7.2.1 Product A
    4.7.2.2 Product B
  4.7.3 Astellas Pharma Inc. Benign Prostatic Hyperplasia Medication Sales (), Revenue (Million USD), Price () and Gross Margin (%)(2012-2017)
  4.7.4 Main Business/Business Overview
4.8 AMNEAL PHARMS
  4.8.1 Company Basic Information, Manufacturing Base and Competitors
  4.8.2 Benign Prostatic Hyperplasia Medication Product Category, Application and Specification
    4.8.2.1 Product A
    4.8.2.2 Product B
  4.8.3 AMNEAL PHARMS Benign Prostatic Hyperplasia Medication Sales (), Revenue (Million USD), Price () and Gross Margin (%)(2012-2017)
  4.8.4 Main Business/Business Overview
4.9 ANCHEN PHARMS
  4.9.1 Company Basic Information, Manufacturing Base and Competitors
  4.9.2 Benign Prostatic Hyperplasia Medication Product Category, Application and Specification
    4.9.2.1 Product A
    4.9.2.2 Product B
  4.9.3 ANCHEN PHARMS Benign Prostatic Hyperplasia Medication Sales (), Revenue (Million USD), Price () and Gross Margin (%)(2012-2017)
  4.9.4 Main Business/Business Overview
4.10 APOTEX INC
  4.10.1 Company Basic Information, Manufacturing Base and Competitors
  4.10.2 Benign Prostatic Hyperplasia Medication Product Category, Application and Specification
    4.10.2.1 Product A
    4.10.2.2 Product B
  4.10.3 APOTEX INC Benign Prostatic Hyperplasia Medication Sales (), Revenue (Million USD), Price () and Gross Margin (%)(2012-2017)
  4.10.4 Main Business/Business Overview
4.11 ASCENT PHARMS INC
4.12 AUROBINDO PHARMA
4.13 BARR
4.14 BIONPHARMA INC
4.15 BOEHRINGER INGELHEIM
4.16 BRECKENRIDGE PHARM
4.17 CIPLA LTD
4.18 AUROBINDO PHARMA LIMITED IN 500 038 Hyderabad
4.19 Bioindustria L.I.M. S.p.A. IT 15067 Novi Ligure
4.20 CADILA HEALTHCARE LIMITED IN 391 440 Dabhasa Village
4.21 CIPLA LIMITED IN 400 013 Mumbai
4.22 CRYSTAL PHARMA S.A.U. ES 47151 Boecillo
4.23 DR. REDDY'S LABORATORIES LIMITED IN 500 034 Hyderabad
4.24 EXCELLA GMBH & CO. KG DE 90537 Feucht
4.25 Farmak A.S. CZ 779 00 Olomouc
4.26 HETERO LABS LIMITED IN 500 018 Hyderabad
4.27 Hubei Gedian Humanwell Pharmaceutical Co., Ltd. CN 436 070 E-Zhou
4.28 MSN LABORATORIES PRIVATE LIMITED IN 502 329 Rudraram Village

5 BENIGN PROSTATIC HYPERPLASIA MEDICATION MANUFACTURING COST ANALYSIS

5.1 Benign Prostatic Hyperplasia Medication Key Raw Materials Analysis
  5.1.1 Key Raw Materials
  5.1.2 Price Trend of Key Raw Materials
  5.1.3 Key Suppliers of Raw Materials
  5.1.4 Market Concentration Rate of Raw Materials
5.2 Proportion of Manufacturing Cost Structure
  5.2.1 Raw Materials
  5.2.2 Labor Cost
  5.2.3 Manufacturing Expenses
5.3 Manufacturing Process Analysis of Benign Prostatic Hyperplasia Medication

6 INDUSTRIAL CHAIN, SOURCING STRATEGY AND DOWNSTREAM BUYERS

6.1 Benign Prostatic Hyperplasia Medication Industrial Chain Analysis
6.2 Upstream Raw Materials Sourcing
6.3 Raw Materials Sources of Benign Prostatic Hyperplasia Medication Major Players/Manufacturers in 2016
6.4 Downstream Buyers

7 MARKETING STRATEGY ANALYSIS, DISTRIBUTORS/TRADERS

7.1 Marketing Channel
  7.1.1 Direct Marketing
  7.1.2 Indirect Marketing
  7.1.3 Marketing Channel Development Trend
7.2 Market Positioning
  7.2.1 Pricing Strategy
  7.2.2 Brand Strategy
  7.2.3 Target Client
7.3 Distributors/Traders List

8 MARKET EFFECT FACTORS ANALYSIS

8.1 Technology Progress/Risk
  8.1.1 Substitutes Threat
  8.1.2 Technology Progress in Related Industry
8.2 Consumer Needs/Customer Preference Change
8.3 Economic/Political Environmental Change

9 GLOBAL AND JAPAN BENIGN PROSTATIC HYPERPLASIA MEDICATION MARKET SIZE (SALES AND REVENUE) FORECAST (2017-2022)

9.1 Global and Japan Benign Prostatic Hyperplasia Medication Sales (), Revenue (Million USD) Forecast (2017-2022)
9.2 Global and Japan Benign Prostatic Hyperplasia Medication Sales () Forecast by Type (2017-2022)
  9.2.1 by 5α-reductase inhibitors
  9.2.2 by α-receptor antagonist
  9.2.3 by Plant Preparations
  9.2.4 by Others
9.3 Global and Japan Benign Prostatic Hyperplasia Medication Sales () Forecast by Application (2017-2022)
9.4 Global and Japan Benign Prostatic Hyperplasia Medication Sales () Forecast by Regions (2017-2022)

10 RESEARCH FINDINGS AND CONCLUSION

11 METHODOLOGY AND DATA SOURCE

11.1 Methodology/Research Approach
  11.1.1 Research Programs/Design
  11.1.2 Market Size Estimation
  11.1.3 Market Breakdown and Data Triangulation
11.2 Data Source
  11.2.1 Secondary Sources
  11.2.2 Primary Sources
11.3 Disclaimer
11.4 Author List

List Of Tables

LIST OF TABLES AND FIGURES

Figure Product Picture of Benign Prostatic Hyperplasia Medication
Table Japan Benign Prostatic Hyperplasia Medication Sales (Million Units) Comparison by Applications (2012-2017)
Figure Japan Sales Market Share (%) of Benign Prostatic Hyperplasia Medication by Applications in 2016
Table Global Benign Prostatic Hyperplasia Medication Sales (Million Units) Comparison by Applications (2012-2017)
Figure Global Sales Market Share (%) of Benign Prostatic Hyperplasia Medication by Applications in 2016
Figure urinary surgery Examples
Table Key Downstream Customer in urinary surgery
Figure Pharmacy Examples
Table Key Downstream Customer in Pharmacy
Figure Hospital Examples
Table Key Downstream Customer in Hospital
Figure Clinic Examples
Table Key Downstream Customer in Clinic
Figure Finasteride Product Picture
Figure Dutasteride Product Picture
Figure Epristeride Product Picture
Figure Pheoxbenzamine Product Picture
Figure Doxazosin Product Picture
Figure Alfuzosin Product Picture
Figure Terazosin Product Picture
Figure Prarizonaosin Product Picture
Figure Prostat Product Picture
Figure Cernilton Product Picture
Figure Compound blue palm fruit Product Picture
Figure Flavoxate Product Picture
Figure glu-ala-glycine Product Picture
Table MSD PHARMA (SINGAPORE) PTE.LTD. Basic Information List
Table MSD PHARMA (SINGAPORE) PTE.LTD. Benign Prostatic Hyperplasia Medication Sales (), Revenue (Million USD), Price () and Gross Margin (%)(2012-2017)
Table MSD PHARMA (SINGAPORE) PTE.LTD. Benign Prostatic Hyperplasia Medication Sales Growth Rate (%)(2012-2017)
Table MSD PHARMA (SINGAPORE) PTE.LTD. Benign Prostatic Hyperplasia Medication Sales Market Share (%) in Japan (2012-2017)
Figure MSD PHARMA (SINGAPORE) PTE.LTD. Benign Prostatic Hyperplasia Medication Revenue Market Share (%) in Japan (2012-2017)
Table Merck Sharp & Dohme Limited Basic Information List
Table Merck Sharp & Dohme Limited Benign Prostatic Hyperplasia Medication Sales (), Revenue (Million USD), Price () and Gross Margin (%)(2012-2017)
Table Merck Sharp & Dohme Limited Benign Prostatic Hyperplasia Medication Sales Growth Rate (%)(2012-2017)
Table Merck Sharp & Dohme Limited Benign Prostatic Hyperplasia Medication Sales Market Share (%) in Japan (2012-2017)
Figure Merck Sharp & Dohme Limited Benign Prostatic Hyperplasia Medication Revenue Market Share (%) in Japan (2012-2017)
Table GlaxoSmithKline (Ireland) Limited Basic Information List
Table GlaxoSmithKline (Ireland) Limited Benign Prostatic Hyperplasia Medication Sales (), Revenue (Million USD), Price () and Gross Margin (%)(2012-2017)
Table GlaxoSmithKline (Ireland) Limited Benign Prostatic Hyperplasia Medication Sales Growth Rate (%)(2012-2017)
Table GlaxoSmithKline (Ireland) Limited Benign Prostatic Hyperplasia Medication Sales Market Share (%) in Japan (2012-2017)
Figure GlaxoSmithKline (Ireland) Limited Benign Prostatic Hyperplasia Medication Revenue Market Share (%) in Japan (2012-2017)
Table Pfizer Pharma GmbH Basic Information List
Table Pfizer Pharma GmbH Benign Prostatic Hyperplasia Medication Sales (), Revenue (Million USD), Price () and Gross Margin (%)(2012-2017)
Table Pfizer Pharma GmbH Benign Prostatic Hyperplasia Medication Sales Growth Rate (%)(2012-2017)
Table Pfizer Pharma GmbH Benign Prostatic Hyperplasia Medication Sales Market Share (%) in Japan (2012-2017)
Figure Pfizer Pharma GmbH Benign Prostatic Hyperplasia Medication Revenue Market Share (%) in Japan (2012-2017)
Table Sanofi-Aventis France Basic Information List
Table Sanofi-Aventis France Benign Prostatic Hyperplasia Medication Sales (), Revenue (Million USD), Price () and Gross Margin (%)(2012-2017)
Table Sanofi-Aventis France Benign Prostatic Hyperplasia Medication Sales Growth Rate (%)(2012-2017)
Table Sanofi-Aventis France Benign Prostatic Hyperplasia Medication Sales Market Share (%) in Japan (2012-2017)
Figure Sanofi-Aventis France Benign Prostatic Hyperplasia Medication Revenue Market Share (%) in Japan (2012-2017)
Table ABBOTT LABORATORIES Basic Information List
Table ABBOTT LABORATORIES Benign Prostatic Hyperplasia Medication Sales (), Revenue (Million USD), Price () and Gross Margin (%)(2012-2017)
Table ABBOTT LABORATORIES Benign Prostatic Hyperplasia Medication Sales Growth Rate (%)(2012-2017)
Table ABBOTT LABORATORIES Benign Prostatic Hyperplasia Medication Sales Market Share (%) in Japan (2012-2017)
Figure ABBOTT LABORATORIES Benign Prostatic Hyperplasia Medication Revenue Market Share (%) in Japan (2012-2017)
Table Astellas Pharma Inc. Basic Information List
Table Astellas Pharma Inc. Benign Prostatic Hyperplasia Medication Sales (), Revenue (Million USD), Price () and Gross Margin (%)(2012-2017)
Table Astellas Pharma Inc. Benign Prostatic Hyperplasia Medication Sales Growth Rate (%)(2012-2017)
Table Astellas Pharma Inc. Benign Prostatic Hyperplasia Medication Sales Market Share (%) in Japan (2012-2017)
Figure Astellas Pharma Inc. Benign Prostatic Hyperplasia Medication Revenue Market Share (%) in Japan (2012-2017)
Table AMNEAL PHARMS Basic Information List
Table AMNEAL PHARMS Benign Prostatic Hyperplasia Medication Sales (), Revenue (Million USD), Price () and Gross Margin (%)(2012-2017)
Table AMNEAL PHARMS Benign Prostatic Hyperplasia Medication Sales Growth Rate (%)(2012-2017)
Table AMNEAL PHARMS Benign Prostatic Hyperplasia Medication Sales Market Share (%) in Japan (2012-2017)
Figure AMNEAL PHARMS Benign Prostatic Hyperplasia Medication Revenue Market Share (%) in Japan (2012-2017)
Table ANCHEN PHARMS Basic Information List
Table ANCHEN PHARMS Benign Prostatic Hyperplasia Medication Sales (), Revenue (Million USD), Price () and Gross Margin (%)(2012-2017)
Table ANCHEN PHARMS Benign Prostatic Hyperplasia Medication Sales Growth Rate (%)(2012-2017)
Table ANCHEN PHARMS Benign Prostatic Hyperplasia Medication Sales Market Share (%) in Japan (2012-2017)
Figure ANCHEN PHARMS Benign Prostatic Hyperplasia Medication Revenue Market Share (%) in Japan (2012-2017)
Table APOTEX INC Basic Information List
Table APOTEX INC Benign Prostatic Hyperplasia Medication Sales (), Revenue (Million USD), Price () and Gross Margin (%)(2012-2017)
Table APOTEX INC Benign Prostatic Hyperplasia Medication Sales Growth Rate (%)(2012-2017)
Table APOTEX INC Benign Prostatic Hyperplasia Medication Sales Market Share (%) in Japan (2012-2017)
Figure APOTEX INC Benign Prostatic Hyperplasia Medication Revenue Market Share (%) in Japan (2012-2017)
Table ASCENT PHARMS INC Basic Information List
Table AUROBINDO PHARMA Basic Information List
Table BARR Basic Information List
Table BIONPHARMA INC Basic Information List
Table BOEHRINGER INGELHEIM Basic Information List
Table BRECKENRIDGE PHARM Basic Information List
Table CIPLA LTD Basic Information List
Table AUROBINDO PHARMA LIMITED IN 500 038 Hyderabad Basic Information List
Table Bioindustria L.I.M. S.p.A. IT 15067 Novi Ligure Basic Information List
Table CADILA HEALTHCARE LIMITED IN 391 440 Dabhasa Village Basic Information List
Table CIPLA LIMITED IN 400 013 Mumbai Basic Information List
Table CRYSTAL PHARMA S.A.U. ES 47151 Boecillo Basic Information List
Table DR. REDDY'S LABORATORIES LIMITED IN 500 034 Hyderabad Basic Information List
Table EXCELLA GMBH & CO. KG DE 90537 Feucht Basic Information List
Table Farmak A.S. CZ 779 00 Olomouc Basic Information List
Table HETERO LABS LIMITED IN 500 018 Hyderabad Basic Information List
Table Hubei Gedian Humanwell Pharmaceutical Co., Ltd. CN 436 070 E-Zhou Basic Information List
Table MSN LABORATORIES PRIVATE LIMITED IN 502 329 Rudraram Village Basic Information List
Table Production Base and Market Concentration Rate of Raw Material
Figure Price Trend of Key Raw Materials
Table Key Suppliers of Raw Materials
Figure Manufacturing Cost Structure of Benign Prostatic Hyperplasia Medication
Figure Manufacturing Process Analysis of Benign Prostatic Hyperplasia Medication
Figure Benign Prostatic Hyperplasia Medication Industrial Chain Analysis
Table Raw Materials Sources of Benign Prostatic Hyperplasia Medication Major Players/Manufacturers in 2016
Table Major Buyers of Benign Prostatic Hyperplasia Medication
Table Distributors/Traders List
Figure Japan Benign Prostatic Hyperplasia Medication Sales () and Growth Rate (%) Forecast (2017-2022)
Figure Japan Benign Prostatic Hyperplasia Medication Revenue (Million USD) and Growth Rate Forecast (2017-2022)
Figure Japan Benign Prostatic Hyperplasia Medication Price () Trend Forecast (2017-2022)
Figure Global Benign Prostatic Hyperplasia Medication Sales () and Growth Rate (%) Forecast (2017-2022)
Figure Global Benign Prostatic Hyperplasia Medication Revenue (Million USD) and Growth Rate Forecast (2017-2022)
Figure Global Benign Prostatic Hyperplasia Medication Price () Trend Forecast (2017-2022)
Table Japan Benign Prostatic Hyperplasia Medication Sales () Forecast by Type (2017-2022)
Table Global Benign Prostatic Hyperplasia Medication Sales () Forecast by Type (2017-2022)
Figure Japan Benign Prostatic Hyperplasia Medication Sales () Forecast by Type (2017-2022)
Figure Global Benign Prostatic Hyperplasia Medication Sales () Forecast by Type (2017-2022)
Figure Japan Benign Prostatic Hyperplasia Medication Sales Volume Market Share Forecast by Type in 2017
Figure Global Benign Prostatic Hyperplasia Medication Sales Volume Market Share Forecast by Type in 2017
Table Japan Benign Prostatic Hyperplasia Medication Sales () Forecast by Application (2017-2022)
Figure Japan Benign Prostatic Hyperplasia Medication Sales Volume Market Share Forecast by Application (2017-2022)
Figure Japan Benign Prostatic Hyperplasia Medication Sales Volume Market Share Forecast by Application in 2017
Table Global Benign Prostatic Hyperplasia Medication Sales () Forecast by Application (2017-2022)
Figure Global Benign Prostatic Hyperplasia Medication Sales Volume Market Share Forecast by Application (2017-2022)
Figure Global Benign Prostatic Hyperplasia Medication Sales Volume Market Share Forecast by Application in 2017
Table Japan Benign Prostatic Hyperplasia Medication Sales () Forecast by Regions (2017-2022)
Table Japan Benign Prostatic Hyperplasia Medication Sales Volume Share Forecast by Regions (2017-2022)
Figure Japan Benign Prostatic Hyperplasia Medication Sales Volume Share Forecast by Regions (2017-2022)
Table Global Benign Prostatic Hyperplasia Medication Sales () Forecast by Regions (2017-2022)
Table Global Benign Prostatic Hyperplasia Medication Sales Volume Share Forecast by Regions (2017-2022)
Figure Global Benign Prostatic Hyperplasia Medication Sales Volume Share Forecast by Regions (2017-2022)
Table Research Programs/Design for This Report
Figure Bottom-up and Top-down Approaches for This Report
Figure Data Triangulation
Table Key Data Information from Secondary Sources
Table Key Data Information from Primary Sources